Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nano-Megestrol Acetate in Advanced Pancreatic Cancer with Anorexia-Cachexia Syndrome
NCT07408505Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of megestrol in cancer anorexia-cachexia syndrome (CACS) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: Proportion of Patients Achieving >5% Weight Gain From Baseline at 12 weeks. Started Jun 2026; status: recruiting.
02
Drugs
megestrol
03
Conditions
cancer anorexia-cachexia syndrome (CACS)
Beyond the preview
Go deeper on NCT07408505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07408505.